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Abstract
Life expectancy for people diagnosed with HIV has improved dramatically however the number of new infections in
the UK remains high. Understanding patterns of sexual behaviour among people living with diagnosed HIV, and the
factors associated with having condom-less sex, is important for informing HIV prevention strategies and clinical
care. In addition, in view of the current interest in a policy of early antiretroviral treatment (ART) for all people
diagnosed with HIV in the UK, it is of particular importance to assess whether ART use is associated with increased
levels of condom-less sex. In this context the ASTRA study was designed to investigate current sexual activity, and
attitudes to HIV transmission risk, in a large unselected sample of HIV-infected patients under care in the UK. The
study also gathered background information on demographic, socio-economic, lifestyle and disease-related
characteristics, and physical and psychological symptoms, in order to identify other key factors impacting on HIV
patients and the behaviours which underpin transmission. In this paper we describe the study rationale, design,
methods, response rate and the demographic characteristics of the participants. People diagnosed with HIV infection
attending 8 UK HIV out-patient clinics in 2011-2012 were invited to participate in the study. Those who agreed to
participate completed a confidential, self-administered pen-and-paper questionnaire, and their latest CD4 count and
viral load test results were recorded. During the study period, 5112 eligible patients were invited to take part in the
study and 3258 completed questionnaires were obtained, representing a response rate of 64% of eligible patients.
The study includes 2248 men who have sex with men (MSM), 373 heterosexual men and 637 women. Future results
from ASTRA will be a key resource for understanding HIV transmission within the UK, targeting prevention efforts,
and informing clinical care of individuals living with HIV.
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Introduction
Effective anti-retroviral therapy (ART) has resulted in a
dramatic improvement in life expectancy for those infected with
Human Immunodeficiency Virus (HIV) [1] [2] [3], at the same
time as an increase in HIV prevalence in the United Kingdom
(UK). About 96,000 people were estimated to be living with HIV
in the UK in 2011 of whom 24% are undiagnosed [4]. Of the
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96,000 it is estimated that 40,100 (42%) are men who acquired
HIV from sex with men, 51,500 (54%) are men and women
who acquired HIV through heterosexual sex and 2,300 (3%)
acquired HIV through sharing drug injection equipment. The
majority of those acquiring HIV through heterosexual sex
(around 60%) are of African origin. Of those who are aware of
their HIV infection and are under care, about 84% are taking
ART. Despite continued prevention efforts, the numbers of new
HIV infections detected in the UK continues to rise among men
who have sex with men (MSM), with over 3000 new diagnoses
in 2011 [4]. Many individuals infected with HIV by heterosexual
transmission were born outside the UK and acquired HIV in
their country of origin, however there is evidence of ongoing
heterosexual transmission within the UK [5] [6].
HIV incidence in the UK is primarily driven by patterns of
sexual risk behaviour among people with and without HIV
infection. The key risk behaviour is referred to here as the
amount of ‘condom-less sex’ within the population, but at an
individual level transmission risk is also dependent on numbers
and types of sexual partner as well as the number of vaginal or
anal sex acts without a condom. Community-based studies
have reported that, from the mid-1990s until recently, rates of
condom-less anal intercourse have increased among MSM [7]
[8] [9] [10] [11]. These trends occurred co-incident with the
advent of effective ART, raising debate as to whether a new
optimism surrounding HIV treatment and prognosis was one of
the driving factors in changes in risk behaviour [12] [13].
Among HIV-infected individuals, a significant proportion of
MSM (10-30%), and a lower proportion of heterosexual
individuals, report recent condom-less sex with partners of HIV-
negative status or unknown HIV status [11] [14] [15] [16] [17]
[18] [19] [20], thereby posing a risk of HIV transmission to an
uninfected person. An important question is whether use of
ART tends to lead to increases in condom-less sex at an
individual level. Early evidence gave little suggestion of this
phenomenon. A meta-analysis based on studies from 1996 to
2003 showed that there was considerable heterogeneity in
study results concerning the association of ART use with
sexual risk behaviour (with several statistically significant
results in both directions), but overall found no evidence of
association when combining these differing estimates [21].
Subsequent studies based in HIV clinics (carried out up to
2005) found either no association between ART use (and/or
viral suppression) and sexual risk behaviour [15] [18], or have
found that patients on ART in fact tended to have somewhat
lower levels of sexual risk behaviour than patients not taking
ART [22] [23]. Similarly, in the SMART trial of treatment
interruption, the ART continuation treatment strategy was
associated with lower rates of sexual risk behaviour than the
ART interruption treatment strategy [24].
However, over recent years there has been a fundamental
change in the messages and information received by HIV-
infected individuals regarding transmission risk. There has
been increasing awareness that successful virological
suppression with ART may lead to a profound reduction in an
individual’s infectiousness.
In 2008, an internationally well respected group of Swiss HIV
clinicians and researchers issued a statement indicating that
the risk of transmitting HIV through unprotected sex is
extremely low if the infected partner has a suppressed plasma
viral load and no other sexually transmitted disease [25]. The
“Swiss Statement” received widespread attention in the UK and
world-wide, and caused huge controversy and debate [26].
Recent information from The Swiss HIV Cohort Study suggests
that sexual behaviour patterns may be changing among HIV
diagnosed individuals in Switzerland, with participants in stable
partnerships on ART reporting higher levels of condom-less
sex since the publication of the “Swiss Statement.” [27].
However, the effect of these changing messages about ‘safe
sex’ on the sexual lifestyles of HIV-diagnosed individuals in the
UK is not known. The interplay between ART use, perceived
viral load status, and sexual behaviour may be complex: few
existing studies have assessed the role of potentially important
co-factors [21], such as time since diagnosis, time since
starting ART, ART side-effects, health and well-being,
psychological distress, HIV disclosure, and specific beliefs
regarding viral suppression and infectiousness. In addition, the
extent to which HIV-diagnosed individuals have accurate
knowledge of their latest viral load is unclear.
The evidence that reductions in HIV viral load are associated
with a decrease in infectivity comes from longitudinal studies
[28], population studies [29], and more recently from a
randomised trial. In the HPTN 052 trial, it was found that
successful reduction of viral load via early ART resulted in a
significantly reduced risk of HIV transmission between
heterosexual individuals in stable partnerships [30]. There is
therefore increasing interest in a policy of ART for all
individuals who are diagnosed with HIV in the UK (rather than
delaying ART until an individual’s CD4 count falls below
350/mm3 as is recommended in current British HIV Association
guidelines)[31] [32]. A policy of early ART for all people
diagnosed with HIV would have the potential to reduce HIV
transmission via reduction in infectiousness of HIV-diagnosed
individuals. However, the individual clinical benefit of early
versus delayed ART is uncertain, and is currently being
evaluated in an international randomised trial which is expected
to finish in 2016 (the START Study – http://
www.thestartstudy.org).
Understanding the current relationship between ART use,
viral suppression and sexual behaviour among HIV-diagnosed
individuals is particularly important. If ART use were to be
associated with significant changes in sexual behaviour, in
particular a substantial increase in levels of condom-less sex,
this could potentially offset or lessen the impact of a policy of
early ART on HIV transmission.
In this context the ASTRA study was designed to investigate
current patterns of sexual behaviour in a large unselected
sample of HIV-infected patients under care in the UK, and
among key demographic subgroups (MSM; Black African men
and women; recently diagnosed people), and to assess the
associations of ART use, perceived viral suppression, and
other factors with condom-less vaginal or anal sex. The study
is intended to help improve understanding of the current link
between ART use and sexual behaviour which is particularly
important in assessing the potential public health impact of a
strategy of early ART. The study also directly investigated
The ASTRA Study
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attitudes to starting ART among HIV patients not currently
treated, and will therefore provide information on the
acceptability of a strategy of widespread treatment and on
attitudes to starting ART early to reduce infectiousness, if there
is no clinical benefit to individual health.
The detailed objectives of the ASTRA study are as follows:
(i) to assess patterns of sexual behaviour among HIV-
diagnosed patients under care in the UK, and to estimate levels
of recent condom-less vaginal or anal sex with partners of
unknown or negative HIV status, according to key demographic
subgroups (MSM, Black African men and women, recently
diagnosed people)
(ii) to assess whether ART use, self-reported current
undetectable viral load, and other factors (demographic/social
factors, psychological and physical symptoms, quality of life,
lifestyle factors, HIV-related factors, time since starting ART
and ART adherence) are associated with condom-less sex with
HIV-negative or unknown status partners
(iii) to investigate patients’ beliefs regarding the effect of
ART, and undetectable viral load, on HIV transmission risk
(transmission risk beliefs), and the association of transmission
risk beliefs with sexual behaviour
(iv) to assess the association between self-reported and
clinically-documented viral load status
(v) to investigate attitudes to starting immediate ART, among
ART naïve patients and to assess whether transmission risk
beliefs and demographic, health, lifestyle and HIV-related
factors are associated with these attitudes
(vi) to assess the prevalence of, and interrelationships
between questionnaire-assessed health and lifestyle factors
among HIV-diagnosed patients
(vii) in a subset of patients, to investigate the association of
questionnaire-assessed factors with laboratory and clinical
outcomes (including virological failure, and major morbidity and
mortality).
The current paper sets out the key aspects underlying the
ASTRA study, including its rationale, design, methods,
response rate and the demographic characteristics of the
participants. Subsequent publications will address detailed
research questions based on the data collected from the
participants.
Design and Methods
Population and setting
A cross-sectional self-administered questionnaire study was
conducted at eight out-patient HIV clinics in the UK. The study
aimed to include a sample of all the HIV out-patients attending
at each centre, regardless of ART status. The exclusion criteria
were as follows: those under 18; those unable to understand
the questionnaire due to language or cognitive difficulties; and
those too ill or distressed to complete the questionnaire.
Additionally the recruitment period was of sufficient duration
(~12 months) so that infrequent clinic attenders were likely to
be included in those invited to participate.
The eight clinical centres were selected based on previously
successful research collaborations and on the understanding
that they could provide access to significant numbers of HIV
diagnosed patients, including the key demographic subgroups
in the UK (MSM and Black Africans). The centres were as
follows:
• Royal Sussex County Hospital, Brighton
• Eastbourne Sexual Health Clinic
• Homerton University Hospital, London
• Mortimer Market Clinic, London
• Newham University Hospital, London
• North Manchester General Hospital
• Royal Free Hospital, London
• Whipps Cross University Hospital, London
Seven of the eight clinics have a patient population size
greater than the national average of 332 (based on the 211 HIV
out-patient clinics in England, Wales and Northern Ireland [33]).
Further details of recruitment periods and the estimated total
patient population for each clinic are shown in Table 1.
Sample size
The sample size for ASTRA was calculated to detect an
absolute difference of 4% in the overall proportion of
participants reporting condom-less sex with an HIV-negative or
unknown HIV-status partner (CLS-D), comparing those taking
ART and those not taking ART. The calculations were based
on 80% power and 5% 2-sided significance level and assumed
that 75% of HIV out-patients are on ART and the proportion of
patients off ART reporting CLS-D is 12% [15] [17] [18] [19] [20].
The required sample size based on these assumptions was
3349 participants.
Recruitment
Recruitment to the study took place between February 2011
and December 2012 at different periods in the 8 centres (full
details in Table 1). A flowchart of recruitment procedures for
the study is included (see Figure 1).
The study clinic teams identified specific routine clinical
sessions during which recruitment would take place throughout
the study period. During these selected recruitment sessions,
consecutive eligible patients were approached by clinic staff
and invited to participate. In some clinics this process took
place in the waiting area; in others it took place during routine
consultations.
Patients who expressed an interest were given a patient
information sheet that contained full details of the research
project, including contact details for the research team. The
research staff explained the purpose of the study and its
potential benefits and answered any questions or concerns
(see the ‘Ethics’ section below for a summary of measures
undertaken to address patient issues).
If the patient agreed to participate they were required to sign
the study consent form. As part of the consent process it was
explained that the latest viral load and CD4 count would be
recorded for all those participating, but there was also an
optional agreement to allow linkage of participants’
questionnaire data with further routine clinical information (see
the ‘Linked clinical data’ section below for further details on
linked clinical data).
The ASTRA Study
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Figure 1.  Flowchart of ASTRA clinic recruitment and questionnaire collection procedures.  
doi: 10.1371/journal.pone.0077230.g001
The ASTRA Study
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Where possible, participants were encouraged to complete
the questionnaire at the clinic (either before or after their
appointment, or while waiting for tests or prescriptions). In
several clinics, participants could maintain sufficient privacy in
the waiting area to complete questionnaires there (although all
participants were made aware that they could ask for a private
area if necessary). In other clinics a separate private room
away from the waiting area was routinely used for completing
the questionnaire. If the participant could not spare the time to
complete the questionnaire in clinic, he/she was requested to
take the questionnaire away from the clinic, complete it, and
return it using a provided pre-paid envelope addressed to the
study management centre.
Participants were told that the questionnaire would take
between 15 and 30 minutes to complete. They were also given
an envelope and asked to seal the completed questionnaire in
it to ensure that their answers were kept confidential from clinic
staff. Completed questionnaires were collected in the clinic and
transferred regularly to the study management centre.
For patients who took the questionnaire off site, there were
procedures for reminding those who did not return it within a
period of approximately one month. In some clinics text
message reminders were sent or phone calls made to those
who had not returned questionnaires. In other clinics, those
attending for repeat appointments were identified and reminded
personally by clinical staff.
Data processing
Questionnaires were identified only by a unique study
number and participants were instructed not to write their name
or clinic number on the questionnaire to maintain their
anonymity (see the ‘Ethics’ section below for a summary of
measures undertaken to ensure confidentiality).
Details of all the clinic attendees approached for the study
were collected in a study log maintained securely and updated
daily at each clinical site. The study log contained study
numbers, clinic identifiers and details of consent status for all
patients invited to participate in the study. The latest viral load
and CD4 count was recorded for those who agreed to
participate. Clinic research staff were asked to enter the latest
laboratory result values known to the participant at the time the
questionnaire was issued. Contact details of participants were
also entered in the log if the participant had agreed to receive
reminders to return the questionnaire. Information from the
study log at each clinical centre was transferred on a regular
basis to the study management centre. The information
transferred did not include clinic identifiers or contact details of
the participants, ensuring that the version of the study log held
at the study management centre was effectively anonymised.
Regular reports were sent from the study management
centre to each site during the recruitment period, detailing
trends and overall progress in recruitment for each of the study
sites. In addition regular checks were made on the
completeness and quality of the study log and its concordance
with received questionnaires. A further checking process
identified 72 cases where participants filled out a questionnaire
more than once. In these cases only the first completed
questionnaire was included in the analysis.
Questionnaires received at the management centre were
digitised by an external data processing contractor. Each paper
questionnaire was checked for legibility, digitally scanned and
the resulting images were used as the source for two manual
data entry rounds with subsequent quality checking. The
completed data entry batches delivered by the contractor were
checked for accuracy at the study management centre by fully
examining a 5% sample (169 questionnaires). The data entry
error rate using this method was found to be 0.06%.
The original anonymised study datasets, including scanned
images of the questionnaires are stored at the study
management centre in encrypted digital form. They are
preserved by being duplicated and stored on managed servers
with regular backup and professional administration. The
original paper questionnaires are stored securely in locked
cabinets. The study datasets will be made freely and readily
available to the research community after a suitable interval in
a form that ensures that participant anonymity and
confidentiality is maintained.
Study questionnaire
An initial questionnaire design was printed in A4 format and
piloted at 4 study sites in December 2010, using the
recruitment procedures described above. Following feedback
from participants and research staff, a few minor revisions were
made to the final questionnaire, the patient information sheet
and consent form. These changes were submitted as
amendments for ethical approval and were incorporated into
the final version employed during the main recruitment period,
which commenced in February 2011.
The final questionnaire consisted of a printed A5 booklet,
with versions for men (28 page questionnaire) and women (24
page questionnaire). Translated French versions of both
questionnaires were also available in A4 format. However
uptake of this option was minimal (n=14).
The study originally envisaged that sites would employ the
option of either paper questionnaires or a computer assisted
self-interviewing (CASI) version on a small handheld laptop.
The CASI version of the questionnaire was developed and
tested as part of the study. However, initial assessments
showed that there were difficulties managing the administration
of both versions concurrently, particularly for a single staff
member aiming to recruit significant numbers of participants
each day. Patients and staff also preferred using the paper
version. Therefore the paper version was used exclusively at
all sites throughout the study.
The questionnaire sought detailed information on the
following factors:
• Demographic and social factors: including gender, date
of birth ethnicity, education, employment, housing, financial
status, religion, sexuality, relationship status (whether in long-
term partnership and HIV-status of partner), country of birth,
time living in the UK (if non-UK birth) immigration status,
number of children
• HIV-related factors: diagnosis date, number of years
attended the current clinic, current CD4 count (grouped into
five categories including ‘don’t know’), likely route of infection,
disclosure of HIV status
The ASTRA Study
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• Health, symptoms and well-being:
• Physical and psychological symptoms (modified version of
Memorial Symptom Assessment Scale Short-Form) [34] [35]
• Depression (PHQ-9) [36]
• Anxiety (GAD-7) [37]
• Health-related quality of life (EuroQoL 5D) [38]
Social support (modified version of the Duke–UNC
Functional Social Support Questionnaire – FSSQ) [39]
• Relevant medical history: including recently diagnosed
sexually transmitted infections (STIs), symptoms of STIs,
diagnosed hepatitis C, treatment for depression, treatment for
other mental health problems, pregnancy status for women
• HIV-transmission risk: whether transmission risk recently
discussed with clinical staff, beliefs about transmission risk in
relation to ART and undetectable viral load
• ART-related factors:
• for those who had ever taken ART: date of starting ART,
reasons for starting ART, perceptions about the difficulty of
taking ART compared to expectations, latest viral load
(‘undetectable’, ‘detectable’ or ‘don’t know’), whether ever
switched ART due to virological failure; whether currently on
ART (with reasons for stopping if applicable), recent non-
adherence (with reasons) for current ART users only;
• for those who had never taken ART: preferences about
starting treatment immediately if it were shown to (i) slightly
reduce risk of serious illness and (ii) reduce infectiousness to a
sexual partner; whether been advised to start ART (with
reasons for not starting if applicable)
• Lifestyle factors: cigarette smoking status, usual alcohol
intake, evidence of alcohol dependency (the CAGE
questionnaire) [40], recent use of recreational drugs (with
details) and recent use of injecting drugs
• Sexual activity: sexual activity (vaginal or anal sex) during
the previous 3 months was ascertained separately for (i) men
having sex with women (ii) men having sex with men (iii)
women having sex with men. There were questions on number
of partners, type of partners (long-term or other), condom-less
sex with HIV-positive and HIV-negative/unknown status
partners (CLS-D). For those participants who reported CLS-D
in the past 3 months, there was detailed inquiry on number and
type of partners, frequency of sex, type of sex (receptive or
insertive anal sex and whether ejaculation occurred), reasons
for not using a condom. All participants were also asked about:
use of the internet to find sexual partners; group sex; receiving
money or drugs for sex; whether partners had used PrEP (pre
exposure prophylaxis) or PEPSE (post exposure prophylaxis
after sexual exposure to HIV) to reduce the risk of HIV
transmission; attitudes to disclosure of HIV to sexual partners
and negotiation of condom use; and their total number of new
sexual partners in the past year.
PDF copies of the questionnaires are available for download
from the study website (http://www.astra-study.org). Paper
versions are also available on request.
Linked clinical data
Basic consent to participate in the study included permission
to collect the latest CD4 count and HIV plasma viral load
values (with dates) known to each participant and these details
were recorded in the study log.
Participants were also asked if they would consent to linkage
of questionnaire data with their routine clinical data for this
study over the next few years. They were told that this was an
optional consent and that they could refuse and still participate
in the questionnaire part of the study. The clinical data
consisted of laboratory test results (including CD4 count and
viral load), HIV treatment history, and other routinely available
information on HIV clinical care including Acquired
Immunodeficiency Syndrome (AIDS) events, serious illnesses,
hospital admissions and dates of death where appropriate.
For consenting subjects, the first linkage of questionnaire
data with clinical data took place shortly after the end of study
recruitment. Subsequent linkages will occur on up to four
additional occasions over the next five years (to allow for
prospective analyses). Clinical data are provided by the clinics
for each consenting participant based on study number. Clinic
identifiers are not transferred to the study management centre,
ensuring that the clinical data are effectively anonymised.
The clinical data for the study are stored at the study
management centre in encrypted digital form. They are
preserved by being duplicated and stored on managed servers
with regular backup and professional administration.
Ethics statement
The research protocol and all versions of the study
documents (information sheet, consent form and questionnaire)
were approved by the North West London REC 2 research
ethics committee (ref 10/H0720/70). Based on these
documents, the study subsequently received permission for
clinical research at all participating National Health Service
sites.
A summary of the measures taken to ensure the
confidentiality and security of patient information is as follows:
1. care was taken to ensure the privacy of participants during
questionnaire completion
2. participants were assured that their questionnaire
responses would not be seen by clinic staff or recorded in clinic
notes (completed questionnaires were stored in sealed
envelopes and not made available to the local clinic staff)
3. data stored at the study management centre was identified
only by an anonymous study number and did not contain
sufficient detail to allow personal identification of responses
during the data processing stage
4. measures were undertaken to ensure data security at the
study management centre
5. the information sheet included a commitment to
aggregated analysis with no individual data to be revealed
A summary of the measures taken to ensure that study
participants could consider the issues effectively and discuss
any concerns is as follows:
1. in the patient information sheet, participants were made
aware that they could withdraw at any stage; they were also
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offered contact with clinical staff to discuss any issues of
concern
2. the questionnaire noted that participants could leave out
any of the questions; it also gave details of an HIV helpline and
included a comments box at the end for participants to express
their opinions of the study
3. a study website was set up (http://www.astra-study.org)
providing access to full contact details, progress updates,
background information, all the study documents and future
results
Study management
The study was managed on a day to day basis by a core
group of four staff at the research centre: the HIV Epidemiology
and Biostatistics Group, Research Department of Infection and
Population Health, Royal Free Campus, University College
London.
An advisory group was also established at the start of the
study to provide guidance and support. The advisory group
consisted of representatives from University College London,
the University of Liverpool, HIV i-Base, the Department of
Public Health in Colorado, the London School of Hygiene and
Tropical Medicine and City University London.
Results
Recruitment
Over the two year study period a total of 5112 eligible
patients were approached and asked to participate in the study.
Of those approached, 4200 (82%) gave consent to take part in
the study. Of those consenting, 3792 (90%) agreed to linkage
of their questionnaire responses with routine clinical data. The
number of questionnaires finally collected was 3258 and thus
the response rate was 64% (3258/5112) of eligible patients
approached and 78% (3258/4200) of those who gave consent.
2983 of the 3258 respondents (92%) agreed to linkage of their
questionnaire responses with routine clinical data.
Of the 4200 consenting participants, 942 did not return a
questionnaire. However when using the limited information
recorded in the study log to compare those that did (n=3258)
and did not (n=942) return questionnaires, these groups were
found to be similar in terms of gender (% female: 19.6% versus
21.5% for returners and non-returners respectively, χ2(1) = 1.8,
p = 0.18), proportion with HIV viral load ≤50c/mL (76.3% versus
76.4%, χ2(1) = 0.008, p = 0.93) and proportion with CD4 count
<350/mm3 (18.6% versus 21.3%, χ2(1) =3.3, p=0.07).
The eight participating clinics provided estimates of the
number of patients seen in all clinical sessions over the same
period. A total of 12566 patients attended clinic at some point
during the recruitment periods meaning that, during the
selected clinical sessions, the recruiters approached 41%
(5112/12566) of all clinic attendees as part of our study.
Table 1 shows the recruitment periods, patient populations
and response rates for the eight clinical centres.
Characteristics of those recruited
The mean age of the 3258 participants at the time of
questionnaire completion was 45 years (SD=10, range 18-88
years) and the proportions who were <30, 30-39, 40-49, 50-59,
≥60 years were 5%, 23%, 43%, 22% and 7% respectively.
2621 (80%) participants were men and 637 (20%) were
women. Of the male participants, 2248 (86%) were classified
as MSM and 373 (14%) as heterosexual.
In terms of ethnic origin, 2220 (68%) participants were
classified as white, 614 participants (19%) were of Black
African ethnicity, 125 (4%) were of other Black ethnicity, 226
(7%) were of other ethnicity and ethnic status was missing for
73 (2%). Overall, of 3202 participants with information on ART
status, 2765 (86%) reported taking ART at the time of
questionnaire completion.
There were differences between the characteristics of those
recruited at the eight clinical centres in terms of gender, sexual
orientation and ethnic origin (see Table 2).
Discussion
The ASTRA study recruited 3258 participants from eight UK
HIV out-patient clinics during 2011/2012. Although the study
recruited only during selected clinical sessions at each of the
eight clinics, the total number of patients invited to participate
represents a large proportion of all those attending the
participating clinics over the study period (5112/12566 = 41%)
and questionnaires were finally obtained from 26%
(3258/12566) of this total clinic population. The numbers
approached and recruited in the ASTRA study are relatively
large in relation to the size of the UK HIV-diagnosed population
which was estimated to be about 73400 in 2011 [4]. The
patients approached account for approximately 7% of the
national HIV-diagnosed population, and our sample of 3258
included approximately 4.4% of all those living with diagnosed
HIV in the UK.
To our knowledge this is the largest clinic-based
questionnaire study to date of HIV-diagnosed individuals in the
UK. Previous large multicentre studies of HIV out-patients in
the UK include the ‘What do you need’ study (1777 responses
using an opportunistic sample across 107 different UK
organisations in 2001 [41]); the ‘East London Study’ (1687
participants from 6 London centres in 2004/5 [42]); and the
‘Switching Study’ (778 participants from 5 centres in London
and the South East in 2005/6 [19]).
In addition to the large sample size, particular strengths of
the ASTRA study include the collection of comprehensive
information on recent sexual activity (over the previous 3
months), the collection of both self-reported and clinic-recorded
viral load for all study participants, and the very high proportion
of respondents (92%) who agreed to linkage of questionnaire
data with routine clinic data.
The initial rates for consent (82%) and for consent to supply
clinical data (90%) were high in this study. However the overall
response rate (questionnaires received) was 64% of eligible
patients approached. This value is comparable with other
surveys taking place outside the clinical context that have
investigated sexual behaviour (70% - [20]; 65% - [43]), but
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lower than some previous HIV-clinic based pen and paper
questionnaires some of which achieve values above 70% [19]
[42] [44] [45]. It should be noted that the 1854 non-responding
eligible patients were made up of 912 direct refusals to
participate and 942 consenting participants who took a
questionnaire away but did not return it (approximately 18% of
eligible patients in each case). It therefore seems that a major
aspect of the non-response in this study was not related to the
initial patient perceptions of the study but could be attributed to
factors impacting after taking the questionnaires away –
possibly including the length of the questionnaire, a lack of time
to complete it in the clinic, or to participants reassessing the
acceptability of some of the questions outside the clinic setting.
It was not possible to collect any information on those people
who declined to take part in the study. However, the fact that
no major differences were found within the consenting group in
terms of gender, viral load status and prevalence of low CD4
count between those who did and did not return a
questionnaire gives some reassurance that the final study
participants were representative of all those who initially agreed
to take part in terms of demographic and HIV-related factors.
In some key areas, the study population reflected the UK
national HIV diagnosed population. The average age of study
participants was 45 years which is consistent with UK national
data, in that the majority of HIV positive diagnosed individuals
fall into the 35-49 age group [4]. In addition 86% of study
participants reported receiving current antiretroviral therapy
during the 2011-2012 study period, which is compatible with
the UK national estimate for those diagnosed with HIV who are
receiving ART, which is on a rising trend from 71% in 2002 to
84% in 2011 [4].
The study population differs from the UK national HIV
diagnosed population with respect to proportions in key
demographic sub-groups. There were 2248 MSM participants
(69%), 614 Black African participants (19%) and 637 women
(20%). These proportions mean that MSM are over-
represented and Black Africans and women are under-
represented in this study when compared to the percentages
within the UK diagnosed HIV positive population as a whole
(heterosexuals born in Africa - 32%, MSM - 43%, heterosexual
women - 32% [4]). Nevertheless the ASTRA study has
succeeded in its aim to recruit large numbers within the
population groups most affected by HIV in the UK, namely
MSM and Black African men and women.
The demographic characteristics of the participants also
varied greatly between the different clinics, reflecting their
different locations and local populations. Nevertheless the
majority of participants (2319 = 71%) were recruited in London.
This is relevant because the UK HIV epidemic is concentrated
in London with most new diagnoses (42% in 2011) occurring
there and it is where most UK local authorities with a high
prevalence of diagnosed HIV infection are concentrated [4].
In summary, the size and recruitment characteristics of this
study mean that it is a substantive sample of those diagnosed
with HIV in the UK. Its results will therefore have implications
for understanding HIV transmission within the UK, and for
targeting of national prevention efforts. The results will also
give further insights into the relationships between socio-
demographic factors, physical and psychological symptoms,
lifestyle factors, health-related quality of life and ART outcomes
among individuals living with HIV in the UK.
Acknowledgements
We would like to thank all the study participants for their time
and effort. We gratefully acknowledge the contributions and
efforts of all the Astra clinic teams including: Aderonke Adebiyi,
Damilola Awosika, Christina Broussard, Yvonne Clowes, Sue
Cross, Jennifer Cullie, Marina Daskalopoulou, Serge Fedele,
Valerie George, Simon Gilson, Sean Groth, Lewis Haddow,
Wendy Hadley, Lisa Heald, Kerry Hobbs, Martin Jones, Louise
Kerr, Christina Martin, Zandile Maseko, Sifiso Mguni, Cynthia
Murphy, Caron Osborne, Alex Pollard, Robert Pralat, Celia
Richardson, Jas Sagoo, Rosalind Scourse, Cheryl Tawana,
vera Theodore, Andrew Thompson, Gemma Townsend, Sonali
Wayal, Jacqueline Whinney, Julia Williams, Elaney Youssef.
Author Contributions
Conceived and designed the experiments: AP FL AR RG MJ
MF EW JA SE LS SC GH AJ AM JE AG WB. Performed the
experiments: AS FL RG MJ MF EW JA RO ML KA SE JM NP.
Analyzed the data: AS FL. Wrote the manuscript: AS FL AR
AP.
References
1. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P et al. (2003)
Decline in the AIDS and death rates in the EuroSIDA study: an
observational study. Lancet 166: 2572–2576. Available: http://
discovery.ucl.ac.uk/6770/. PubMed: 12853195.
2. May M, Gompels M, Delpech V, Porter K, Post F et al. (2011) Impact of
late diagnosis and treatment on life expectancy in people with HIV-1:
UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (Clin Res Ed) 343:
d6016. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?
artid=3191202&tool=pmcentrez&rendertype=abstract. Accessed 12
February 2013. doi:10.1136/bmj.d6016. PubMed: 21990260.
3. Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V et al.
(2012) Projected life expectancy of people with HIV according to timing
of diagnosis. AIDS 26: 335–343. Available: http://www.ncbi.nlm.nih.gov/
pubmed/22089374. Accessed 12 February 2013. doi:10.1097/QAD.
0b013e32834dcec9. PubMed: 22089374.
4. Health Protection Agency (2012) HIV in the United Kingdom: 2012
Report. Health Protection Services, Colindale. Available: http://
www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317137200016.
Accessed 20 December 2012.
5. Burns FM, Arthur G, Johnson AM, Nazroo J, Fenton KA (2009) United
Kingdom acquisition of HIV infection in African residents in London:
more than previously thought. AIDS 23: 262–266. Available: http://
www.ncbi.nlm.nih.gov/pubmed/19098498. Accessed 3 April 2013. doi:
10.1097/QAD.0b013e32831c546b. PubMed: 19098498.
6. Rice BD, Elford J, Yin Z, Delpech VC (2012) A new method to assign
country of HIV infection among heterosexuals born abroad and
diagnosed with HIV. AIDS 26: 1961–1966. Available: http://
www.ncbi.nlm.nih.gov/pubmed/22781226. Accessed 2 April 2013. doi:
10.1097/QAD.0b013e3283578b80. PubMed: 22781226.
7. Mercer CH, Fenton KA, Copas AJ, Wellings K, Erens B et al. (2004)
Increasing prevalence of male homosexual partnerships and practices
in Britain 1990-2000: evidence from national probability surveys. AIDS
18: 1453–1458. Available: http://search.ebscohost.com/login.aspx?
direct=true&db=cmedm&AN=15199322&site=ehost-live. doi:
10.1097/01.aids.0000131331.36386.de. PubMed: 15199322.
The ASTRA Study
PLOS ONE | www.plosone.org 10 October 2013 | Volume 8 | Issue 10 | e77230
8. Elford J, Bolding G, Davis M, Sherr L, Hart G (2004) Trends in sexual
behaviour among London homosexual men 1998-2003: implications for
HIV prevention and sexual health promotion. Sex Transm Infect 80:
451–454. Available: http://discovery.ucl.ac.uk/167465/. doi:10.1136/sti.
2004.010785. PubMed: 15572612.
9. Dodds JP, Mercey DE, Parry JV, Johnson AM (2004) Increasing risk
behaviour and high levels of undiagnosed HIV infection in a community
sample of homosexual men. Sex Transm Infect 80: 236–240. Available:
http://discovery.ucl.ac.uk/6747/. doi:10.1136/sti.2003.007286. PubMed:
15170012.
10. Hart GJ, Williamson LM (2005) Increase in HIV sexual risk behaviour in
homosexual men in Scotland, 1996–2002: prevention failure? Sex
Transm Infect 81: 367–372. Available: http://discovery.ucl.ac.uk/95388/.
doi:10.1136/sti.2004.013995. PubMed: 16199733.
11. Dodds JP, Johnson AM, Parry JV, Mercey DE (2007) A tale of three
cities: persisting high HIV prevalence, risk behaviour and undiagnosed
infection in community samples of men who have sex with men. Sex
Transm Infect 83: 392–396. Available: http://
www.pubmedcentral.nih.gov/articlerender.fcgi?
artid=2659037&tool=pmcentrez&rendertype=abstract. doi:10.1136/sti.
2006.021782. PubMed: 17472978.
12. Elford J, Bolding G, Sherr L (2002) High-risk sexual behaviour
increases among London gay men between 1998 and 2001: what is the
role of HIV optimism? AIDS 16: 1537–1544. Available: http://
discovery.ucl.ac.uk/6837/. doi:10.1097/00002030-200207260-00011.
PubMed: 12131192.
13. Elford J, Hart G (2005) HAART, viral load and sexual risk behaviour.
AIDS 19: 205–207. Available: http://www.ncbi.nlm.nih.gov/pubmed/
15668547. Accessed 20 December 2012. doi:
10.1097/00002030-200501280-00014. PubMed: 15668547.
14. Fenton KA, Chinouya M, Davidson O, Copas A (2002) HIV testing and
high risk sexual behaviour among London’s migrant African
communities: a participatory research study. Sex Transm Infect 78:
241–245. Available: http://discovery.ucl.ac.uk/145151/. doi:10.1136/sti.
78.4.241. PubMed: 12181459.
15. Kozal MJ, Amico KR, Chiarella J, Schreibman T, Cornman D et al.
(2004) Antiretroviral resistance and high-risk transmission behavior
among HIV-positive patients in clinical care. AIDS 18: 2185–2189.
Available: http://www.ncbi.nlm.nih.gov/pubmed/15577652. doi:
10.1097/00002030-200411050-00011. PubMed: 15577652.
16. Dave SS, Stephenson J, Mercey DE, Panahmand N, Jungmann E
(2006) Sexual behaviour, condom use, and disclosure of HIV status in
HIV infected heterosexual individuals attending an inner London HIV
Clinic. Sex Transm Infect 82: 117–120. Available: http://
discovery.ucl.ac.uk/63096/. doi:10.1136/sti.2005.015396. PubMed:
16581734.
17. Sadler KE, McGarrigle CA, Elam G, Ssanyu-Sseruma W, Davidson O
et al. (2007) Sexual behaviour and HIV infection in black-Africans in
England: results from the Mayisha II survey of sexual attitudes and
lifestyles. Sex Transm Infect 83: 523–529. Available: http://
www.pubmedcentral.nih.gov/articlerender.fcgi?
artid=2598650&tool=pmcentrez&rendertype=abstract. doi:10.1136/sti.
2007.027128. PubMed: 17932129.
18. Elford J, Ibrahim F, Bukutu C, Anderson J (2007) Sexual behaviour of
people living with HIV in London: implications for HIV transmission.
AIDS 21 Suppl 1: S63–S70. Available: http://www.ncbi.nlm.nih.gov/
pubmed/17159590. doi:10.1097/01.aids.0000255087.62223.ff.
PubMed: 17159590.
19. Sherr L, Lampe F, Norwood S, Leake-Date H, Fisher M et al. (2007)
Successive switching of antiretroviral therapy is associated with high
psychological and physical burden. Int J STD AIDS 18: 700–704.
Available: http://discovery.ucl.ac.uk/123785/. doi:
10.1258/095646207782193821. PubMed: 17945049.
20. Williamson LM, Dodds JP, Mercey DE, Hart GJ, Johnson AM (2008)
Sexual risk behaviour and knowledge of HIV status among community
samples of gay men in the UK. AIDS 22: 1063–1070. Available: http://
discovery.ucl.ac.uk/114092/. doi:10.1097/QAD.0b013e3282f8af9b.
PubMed: 18520350.
21. Crepaz N, Hart TA, Marks G (2004) Highly active antiretroviral therapy
and sexual risk behavior: a meta-analytic review. J Am Med Assoc 292:
224–236. Available: http://www.ncbi.nlm.nih.gov/pubmed/15249572.
doi:10.1001/jama.292.2.224. PubMed: 15249572.
22. Stephenson JM, Imrie J, Davis MMD, Mercer C, Black S et al. (2003) Is
use of antiretroviral therapy among homosexual men associated with
increased risk of transmission of HIV infection? Sex Transm Infect 79:
7–10. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?
artid=1744584&tool=pmcentrez&rendertype=abstract. doi:10.1136/sti.
79.1.7. PubMed: 12576605.
23. Glass TR, Young J, Vernazza PL, Rickenbach M, Weber R et al. (2004)
Is unsafe sexual behaviour increasing among HIV-infected individuals?
AIDS 18: 1707–1714. Available: http://content.wkhealth.com/linkback/
openurl?sid=WKPTLP:landingpage&an=00002030-200408200-00012.
doi:10.1097/01.aids.0000131396.21963.81. PubMed: 15280782.
24. Burman W, Grund B, Neuhaus J, Douglas J, Friedland G et al. (2008)
Episodic antiretroviral therapy increases HIV transmission risk
compared with continuous therapy: results of a randomized controlled
trial. J Acquir Immune Defic Syndr 49: 142–150. Available: http://
www.pubmedcentral.nih.gov/articlerender.fcgi?
artid=2749067&tool=pmcentrez&rendertype=abstract. doi:10.1097/QAI.
0b013e318183a9ad. PubMed: 18769356.
25. Vernazza P, Hirschel B, Bernasconi E, Flepp M (2008) Les personnes
séropositives ne souffrant d’aucune autre MST et suivant un traitment
antirétroviral efficace ne transmettent pas le VIH par voie sexuelle.
Bulletin Médecins Suisses 89: 165–169.
26. Bernard E (2008) Swiss experts say individuals with undetectable viral
load and no STI cannot transmit HIV during sex. NAM aidsmap
website. Available: http://www.aidsmap.com/Swiss-experts-say-
individuals-with-undetectable-viral-load-and-no-STI-cannot-transmit-
HIV-during-sex/page/1429357/. Accessed 20 September 2013.
27. Hasse B, Ledergerber B, Hirschel B, Vernazza P, Glass TR et al.
(2010) Frequency and determinants of unprotected sex among HIV-
infected persons: the Swiss HIV cohort study. Clin Infect Dis 51: 1314–
1322. Available: http://www.ncbi.nlm.nih.gov/pubmed/21034200. doi:
10.1086/656809. PubMed: 21034200.
28. Attia S, Egger M, Müller M, Zwahlen M, Low N (2009) Sexual
transmission of HIV according to viral load and antiretroviral therapy:
systematic review and meta-analysis. AIDS 23: 1397–1404. Available:
http://www.ncbi.nlm.nih.gov/pubmed/19381076. doi:10.1097/QAD.
0b013e32832b7dca. PubMed: 19381076.
29. Das M, Chu PL, Santos G-M, Scheer S, Vittinghoff E et al. (2010)
Decreases in Community Viral Load Are Accompanied by Reductions
in New HIV Infections in San Francisco. PLOS ONE 5: 9. Available:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?
artid=2883572&tool=pmcentrez&rendertype=abstract.
30. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC et al.
(2011) Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N
Engl J Med 365: 493–505. Available: http://www.ncbi.nlm.nih.gov/
pubmed/21767103. doi:10.1056/NEJMoa1105243. PubMed: 21767103.
31. Phillips AN, Gazzard BG, Clumeck N, Losso MH, Lundgren JD (2007)
When should antiretroviral therapy for HIV be started? BMJ 334: 76–
78. Available: http://discovery.ucl.ac.uk/118170/. doi:10.1136/bmj.
39064.406389.94. PubMed: 17218713.
32. Neaton JD, Grund B (2008) Earlier initiation of antiretroviral therapy in
treatment-naïve patients: implications of results of treatment
interruption trials. Current Opinion HIV Aids 3: 112–117. doi:10.1097/
COH.0b013e3282f3808b. PubMed: 19372951.
33. (personal communication) Survey Of Prevalent HIV Infections
Diagnosed (SOPHID). Public Health England (2013)
34. Vogl D, Rosenfeld B, Breitbart W, Thaler H, Passik S et al. (1999)
Symptom prevalence, characteristics, and distress in AIDS outpatients.
Elsevier. Available: http://www.ncbi.nlm.nih.gov/pubmed/10534965.
PubMed: 10534965.
35. Chang VT, Hwang SS, Feuerman M, Kasimis BS, Thaler HT (2000)
The memorial symptom assessment scale short form (MSAS-SF).
Cancer 89: 1162–1171. Available: http://www.ncbi.nlm.nih.gov/pubmed/
10964347. doi:10.1002/1097-0142(20000901)89:5. PubMed:
10964347.
36. Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a
brief depression severity measure. J Gen Intern Med 16: 606–613.
Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?
artid=1495268&tool=pmcentrez&rendertype=abstract. doi:10.1046/j.
1525-1497.2001.016009606.x. PubMed: 11556941.
37. Spitzer RL, Kroenke K, Williams JBW, Löwe B (2006) A brief measure
for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med
166: 1092–1097. Available: http://www.ncbi.nlm.nih.gov/pubmed/
16717171. doi:10.1001/archinte.166.10.1092. PubMed: 16717171.
38. EuroQol Group (1990) EuroQol--a new facility for the measurement of
health-related quality of life. The EuroQol Group. Health Policy 16:
199–208. Available: http://www.ncbi.nlm.nih.gov/pubmed/10109801.
doi:10.1016/0168-8510(90)90421-9. PubMed: 10109801.
39. Broadhead WE, Gehlbach SH, De Gruy FV, Kaplan BH (1988) The
Duke-UNC Functional Social Support Questionnaire. Measurement of
social support in family medicine patients. Med Care 26: 709–723.
Available: http://www.jstor.org/stable/3765493. doi:
10.1097/00005650-198807000-00006. PubMed: 3393031.
40. Mayfield D, McLeod G, Hall P (1974) The CAGE questionnaire:
validation of a new alcoholism screening instrument. Am J Psychiatry
The ASTRA Study
PLOS ONE | www.plosone.org 11 October 2013 | Volume 8 | Issue 10 | e77230
131: 1121–1123. Available: http://ajp.psychiatryonline.org/cgi/content/
abstract/131/10/1121. PubMed: 4416585.
41. Weatherburn P, Keogh P, Reid D, Dodds C, Bourne A et al. (2009)
What do you need? 2007-08: a health, social care, support and
information needs assessment of people with diagnosed HIV in the UK.
Sigma Research. Available: http://www.sigmaresearch.org.uk/files/
report2009b.pdf. Accessed 20 December 2012.
42. Elford J, Anderson J, Bukutu C, Ibrahim F (2006) HIV in East London:
ethnicity, gender and risk. Design and methods. BMC Public Health 6:
150. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?
artid=1524742&tool=pmcentrez&rendertype=abstract. doi:
10.1186/1471-2458-6-150. PubMed: 16764715.
43. Johnson AM, Mercer CH, Erens B, Copas AJ, McManus S et al. (2001)
Sexual behaviour in Britain: partnerships, practices, and HIV risk
behaviours. Lancet 358: 1835–1842. Available: http://
www.ncbi.nlm.nih.gov/pubmed/11741621. doi:10.1016/
S0140-6736(01)06883-0. PubMed: 11741621.
44. Rodkjaer L, Laursen T, Balle N, Sodemann M (2010) Depression in
patients with HIV is under-diagnosed: a cross-sectional study in
Denmark. HIV Med 11: 46–53. Available: http://www.scopus.com/
record/display.url?eid=2-
s2.0-72449130446&origin=inward&txGid=QZlSi5X_j7YKeCYnjzlGf0U:
18. doi:10.1111/j.1468-1293.2009.00741.x. PubMed: 19601996.
45. Moses SH, Dhar J (2012) A survey of the sexual and reproductive
health of HIV-positive women in Leicester. Int J STD AIDS 23: 282–
284. Available: http://www.ncbi.nlm.nih.gov/pubmed/22581954. doi:
10.1258/ijsa.2009.009094. PubMed: 22581954.
The ASTRA Study
PLOS ONE | www.plosone.org 12 October 2013 | Volume 8 | Issue 10 | e77230
